Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Avacta selects Trinean’s DropSense96® for purified protein QC

Published: Monday, October 01, 2012
Last Updated: Monday, October 01, 2012
Bookmark and Share
Trinean announced that its DropSense96® droplet reader has been chosen by Avacta for High Throughput analysis of their purified Affimer proteins.

Avacta has established facilities capable of expressing and purifying 15,000 of their proprietary Affimer proteins every 6 weeks. These affinity reagents, which can be thought of as artificial antibodies, will be incorporated into very high complexity protein microarrays designed to revolutionize the discovery and validation of disease biomarkers. “The high complexity of the protein arrays means that the Affimers have to be produced to very high standards of purity and yield." said Paul Ko Ferrigno, Head of Discovery Technology at Avacta, "Our challenge is that quality control becomes a rate-limiting step when working at this high throughput .We currently have plates of purified Affimers stacked waiting for analysis by traditional methods. Once the Trinean DropSense96® is introduced into the workflow, quality control will become as automated as the purification protocols, allowing the development team to go from bacterial colony to purified protein of known concentration within 2 days, processing one thousand proteins at a time."

Philippe Stas, CEO of Trinean, added: "The decision by Avacta to use our DropSense96® droplet reader further validates our instruments to deliver high quality UV/Vis spectral absorbance data. The DropSense96® was designed to meet the requirements of protein purification labs by combining speed and minimal sample usage. Our unmatched large measurement range allows quantification of undiluted protein samples in real-time thereby significantly shortening the purification process.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Trinean Signs a Global Agreement with Bayer CropScience
Bayer will use Trinean’s technology for biomolecule QC using spectral content profiling.
Wednesday, June 12, 2013
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!